New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 17, 2014
09:25 EDTACAD, ACAD, ACAD, JAZZ, JAZZ, JAZZ, FRX, FRX, FRX, MDCO, MDCO, MDCO, SLXP, SLXP, SLXP, VRX, VRX, VRX, VRTX, VRTX, VRTX, SGMO, SGMO, SGMO, PCYC, PCYC, PCYC, PDLI, PDLI, PDLI, ISIS, ISIS, ISIS, HZNP, HZNP, HZNP, GILD, GILD, GILD, CELG, CELG, CELG, BIIB, BIIB, BIIB, BDSI, BDSI, BDSI, NKTR, NKTR, NKTRPiper Jaffray's technical analyst holds an analyst/industry conference call
Senior Technical Analyst Johnson provides an overview of the firm's covered universes, Biotech & Specialty Pharmaceuticals, from the viewpoint of a technical analyst on an Analyst/Industry conference call to be held on January 21 at 10 am.
News For ACAD;BDSI;BIIB;CELG;GILD;HZNP;ISIS;PDLI;PCYC;SGMO;VRTX;VRX;SLXP;MDCO;FRX;JAZZ;NKTR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
December 8, 2014
13:54 EDTCELGCelgene announces results from phase lll Revlimid study
Subscribe for More Information
13:45 EDTPCYCTG Therapeutics says TG-1101 well tolerated in Phase 2 study
Subscribe for More Information
12:25 EDTMDCOAntibiotic makers rise after Merck agrees to buy Cubist
Subscribe for More Information
10:41 EDTISISIsis Pharmaceuticals price target raised to $81 from $62 at Piper Jaffray
Subscribe for More Information
10:11 EDTMDCOHigh option volume stocks
Subscribe for More Information
10:02 EDTGILDGilead presents follow-up data from Zydelig registrational studies
Subscribe for More Information
08:32 EDTPCYCTrout Group to hold events at ASH 2014
Subscribe for More Information
08:00 EDTISISIsis Pharmaceuticals price target raised to $66 from $55 at Stifel
Subscribe for More Information
07:36 EDTCELGAgios announces Celgene to extend discovery phase of collaboration to April 2016
Agios Pharmaceuticals (AGIO) announced that Celgene (CELG) has elected to extend the period of its exclusivity for an additional year to April 2016 under the global strategic collaboration agreement. The two companies have been working together since April 2010 to discover, develop and commercialize disease-altering therapies in oncology arising from Agios' cancer metabolism research platform. The terms of the collaboration extension are consistent with previously agreed upon financial terms. As a result of the extension, Celgene will maintain its exclusive option to drug candidates that emerge from Agios' cancer metabolism research platform through April 2016. Agios will receive a $20M payment. Following this extension, the discovery portion of the collaboration will expire on April 14, 2016. Under the terms of the original agreement announced in April 2010, Agios leads research, preclinical and early development efforts through Phase 1, while Celgene receives an option to obtain exclusive rights either upon IND acceptance or at the end of Phase 1, to further development and commercialize medicines emerging from Agios' cancer metabolism research. Celgene would lead and fund global development and commercialization of some of these drugs, and Agios would retain development and commercialization rights for certain drugs in the United States. On all programs, Agios is eligible to receive up to $120M in milestone-based payments as well as royalties on any sales.
07:29 EDTJAZZ, NKTRUBS to hold investor trip
Subscribe for More Information
07:18 EDTJAZZ, NKTRUBS to hold investor trip
2014 Annual West Coast Investor Trip travels on the West Coast on December 8-10.
07:17 EDTCELGCelgene price target raised to $131 from $120 at Cantor
Subscribe for More Information
07:11 EDTSGMOSangamo presents new data for Vivo Protein Replacement Platform
Sangamo announced the presentation of new preclinical data from its proprietary programs for the treatment of lysosomal storage disorders and Shire-partnered hemophilia program. These studies demonstrate the broad applicability of Sangamo's In Vivo Protein Replacement Platform for the potentially curative treatment of such diseases. The data presented at ASH from Sangamo's proprietary IVPRP applications demonstrated the efficient production, secretion and tissue uptake of functional iduronate-2-sulfatase and alpha-L-iduronidase, enzymes that are deficient in the LSDs, Hunter and Hurler's disease, respectively. Data were also presented from Sangamo's partnered program with Shire that demonstrated that therapeutic levels of Factor IX, the human clotting factor that is deficient in hemophilia B, could be generated in a dose-dependent manner in non-human primates. There were no significant alterations in circulating albumin levels. Studies in mice also demonstrated stable Factor IX production from Sangamo's IVPRP for over 1 year.
07:01 EDTBDSIBioDelivery Sciences completes randomization in trial of clonidine topical gel
BioDelivery Sciences announced that it has completed the randomization of all patients in BDSI's ongoing initial pivotal Phase 3 clinical trial for Clonidine Topical Gel for the treatment of painful diabetic neuropathy. BDSI anticipates that topline results of the study will be available by the end of March 2015. The Phase 3 trial is a multicenter, randomized, double-blind, placebo-controlled study to determine the efficacy and safety of Clonidine Topical Gel in the treatment of pain associated with PDN. In the trial, known as the RHAPSODY Study, subjects were randomized to receive either Clonidine Topical Gel or a placebo gel. Two hundred and sixty three adult subjects were randomized into the 12 week double-blind treatment phase of the study. This is the first of two pivotal trials that would be required for submission of a New Drug Application to the U.S. Food and Drug Administration. FDA has granted Fast Track designation for the program, which recognizes the need of developing new therapies for this serious condition. BDSI plans to begin the second Phase 3 study during the first quarter of 2015.
05:35 EDTCELGCelgene REVLIMID, low-dose dexamethasone increased PFS
Subscribe for More Information
05:30 EDTISISIsis Pharmaceuticals to host conference call
Subscribe for More Information
December 7, 2014
16:40 EDTCELGAgios announces new data from Ongoing Phase 1 trial of AG-221
Subscribe for More Information
14:54 EDTPCYCIMBRUVICA data suggests promise in multiple myeloma
Subscribe for More Information
14:10 EDTCELGAmerican Society of Hematology to hold a meeting
Subscribe for More Information
13:16 EDTCELGCelgene, Acceleron announced data from luspatercept phase 2 clinical trial
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use